Secondary Prophylaxis

In patients who have experienced febrile neutropenia following chemotherapy, chances of a repeat incidence can be avoided by either dose reduction, delay in treatment, or by administration of growth factors. While not all patients who have developed febrile neutropenia with the first cycle of chemotherapy will develop it during subsequent cycles, appropriate actions are needed to avoid potentially fatal future episodes. Recent data with dose-dense, growth factor-supported regimens in patients with malignant lymphomas suggest that prescribing the full planned dose without delay translates into clinical benefits. While dose-dense/intense chemotherapy mandates the use of growth factors, considering that timely administration of chemotherapy is of therapeutic importance, administration of growth factors in general is an important ancillary tool and should be preferred to the strategy of dose adjustment or delay of therapy.11

0 0

Post a comment